Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLN9708 Maintenance After Haploidentical Transplant for High-Risk Hematologic Malignancies
NCT02169791Phase 2Completed
- Sponsor
- Northside Hospital
- Start
- Jul 2014
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ixazomib in acute myeloid leukemia (AML), Chronic Myeloid Leukemia (CML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), sponsored by Northside Hospital. Started Jul 2014; status: completed.
02
Drugs
ixazomib
03
Conditions
acute myeloid leukemia (AML)Chronic Myeloid Leukemia (CML)myelodysplastic syndrome (MDS)acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02169791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02169791.